SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy：a Prospective Exploratory Study (SABRE)

NCT04878107 Phase 2 UNKNOWN

SABRE STUDY will explore effectiveness and safety of the combination therapy of camrelizumab，apatinib and SBRT/LDRT in patients with metastatic non-small Cell Lung Cancer (NSCLC) patient previously treated With PD-1/L1 Inhibitor and Chemotherapy.

Details

Lead sponsor	Wuhan University
Phase	Phase 2
Status	UNKNOWN
Enrolment	88
Start date	2022-03-15
Completion	2023-10

Conditions

• Non-Small Cell Lung Cancer

Interventions

• Camrelizumab
• Apatinib
• Docetaxel injection
• SBRT
• LDRT

Primary outcomes

• Objective response rate — 6 Weeks
  Objective Response Rate at 6 months using RECIST1.1 criteria

Countries

China